IP Library Granted Patent US 8,951,968
Granted Patent B2
US 8,951,968 · App. 13/440,368 · Granted Feb 10, 2015

Methods of treating depression and other related diseases

Inventor: Joseph Moskal (Evanston, IL)
Assignee: Northwestern University
A61K38/07C07K5/081C07K5/0821C07K5/1013C07K5/06139A61K45/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,951,968
App. No.
13/440,368
Granted
Feb 10, 2015
Kind
B2
Abstract

The invention relates to methods for treating depression, anxiety, and other related diseases by administering a peptide NMDAR partial agonist.

Claims (10)

1. A method for treating a patient suffering from major depressive disorder, comprising administering an effective amount of a peptide consisting of the amino acid sequence of SEQ ID NO: 13 where the peptide has an amide modification with having the formula:

or a pharmaceutically acceptable salt thereof to said patient.

2. A method as in claim 1 wherein the effective amount is about 0.01 mg/kg to about 1000 mg/kg per day.

3. The method of claim 1 , wherein said patient is relieved of at least one symptom within about 1 hour to about 12 hours after said administration.

4. The method of claim 1 wherein the pharmaceutically acceptable salt is the acetate salt.

5. The method as in claim 2 wherein the effective amount is about 1 mg/kg to about 10 mg/kg.

6. A method of treating refractory depression in a treatment-resistant patient in need thereof, comprising administering an effective amount of a peptide consisting of the amino acid sequence of SEQ ID NO: 13 where the peptide has an amide modification with the formula:

or a pharmaceutically acceptable salt thereof to said patient, whereby said patient is relieved of at least one symptom within about 14 days.

7. The method of claim 6 , wherein the treatment-resistant patient is identified as one who has been treated with at least two types of antidepressant treatments prior to administration of the peptide.

8. The method of claim 6 , wherein the treatment-resistant patient is identified as one who is unwilling or unable to tolerate a side effect of at least one type of antidepressant treatment.

Assignments (3)
SECURITY INTEREST Recorded Dec 18, 2024
From: GATE NEUROSCIENCES, INC.
To: INNOVIVA TRC HOLDINGS LLC
Reel/Frame 069742/0846 →
SECURITY INTEREST Recorded Nov 6, 2023
From: GATE NEUROSCIENCES, INC.
To: INNOVIVA TRC HOLDINGS LLC
Reel/Frame 065473/0327 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 14, 2012
From: MOSKAL, JOSEPH
To: NORTHWESTERN UNIVERSITY
Reel/Frame 028199/0533 →
Continuity (5)
Continuation In Part PCTUS2010051415 · Oct 5, 2010
Provisional Application 61248650 · Oct 5, 2009
Provisional Application 61471942 · Apr 5, 2011
Provisional Application 61507252 · Jul 13, 2011
Related Publication 20120295852A1 · Nov 22, 2012